Horizon Pharma (HZNP) Stock Tanks on Mixed Earnings

NEW YORK (TheStreet) -- Horizon Pharma (HZNP) closed trading down 6.02% to $27.62 on Friday after the pharmaceutical company released its first-quarter earnings results before the opening bell today.

The company reported a first-quarter net loss of $19.6 million, or 21 cents per share on an adjusted basis, missing analysts' consensus estimates of 23 cents per share by 2 cents. Revenue for the period rose 118% to $113.1 million, topping analysts estimates of $103.7 million.

The company also issued full-year revenue guidance between $590 million and $610 million, well above analysts' $539 million expectations for the year.

Separately, the company announced that it settled patent infringement litigation with generic drug maker Perrigo (PRGO) that grants Perrigo non-exclusive rights to market a generic version of Horizon's arthritis ointment, Pennsaid, in the U.S.

Horizon shares are up 0.36% to $27.72 in after-hours trading today.

HZNP Chart HZNP data by YCharts

Must Read: Warren Buffett's Top 25 Stocks for 2015

More from Markets

Netflix Better Watch Out, Better Not Shout!

Netflix Better Watch Out, Better Not Shout!

Ciena Jumps After Earnings Blow Out Estimates

Ciena Jumps After Earnings Blow Out Estimates

Watch Dollar Valuations as the ECB's Mario Draghi Talks QE: Market Recon

Watch Dollar Valuations as the ECB's Mario Draghi Talks QE: Market Recon

Apple, Adobe, Huawei, CVS and Boy Scouts - 5 Things You Must Know

Apple, Adobe, Huawei, CVS and Boy Scouts - 5 Things You Must Know

Jim Cramer: This May Be an Inflection Point for Banks and Oils

Jim Cramer: This May Be an Inflection Point for Banks and Oils